From the Duke Cancer Institute archives. Content may be out of date.
When Duke Cancer Institute Board of Directors Nancy Wright finished chemotherapy treatment for pancreatic cancer, nurses on the fourth floor of Duke Cancer Center brought out a small bell for her to ring to celebrate.
Feeling inspired, Wright’s family, including her husband, J. Gordon Wright, who 10 years ago this year survived stage 4 lymphoma, donated the Sound of Hope Bell in her honor.
The Wrights stopped by the Seese-Thornton Garden of Tranquility across from Duke Cancer Center to Sound of Hope Bell shortly after it was installed in April 2022.
The Duke Cancer Institute (DCI) has launched a multidisciplinary pancreatic cancer center dedicated to delivering the highest level of care for patients with pancreatic cancer. The center is led by Executive Director Peter Allen, MD, and Deputy Directors Daniel Nussbaum, MD, and John Strickler, MD.The DCI Pancreatic Cancer Center seeks to improve long-term outcomes for patients with or at risk for pancreatic cancer through practice-changing research focusing on prevention, early detection, and treatment."While tremendous progress has been made in treating pancreatic cancer, we recognize that existing standard approaches are simply not good enough," Nussbaum said. "The mission of the DCI Pancreatic Cancer Center is to leverage our clinical and research expertise in order to develop the next generation of therapies for this disease. Our goal is to offer our patients not only standard treatments, which are critically important, but also novel therapies that might improve their chance for cure."Areas of focus include expanding genomic and molecular targeted therapy options, developing the next generation of immunotherapy treatments, and creating novel early detection technologies for pre-malignant or early-stage pancreatic cancer.Patients will have access to innovative clinical trials and individualized treatment protocols through the center."The DCI Pancreatic Cancer Center unites scientists, clinical-investigators, and clinicians toward the shared goal of improving pancreatic cancer survival," Strickler said.
The Duke Cancer Institute (DCI) has launched a multidisciplinary pancreatic cancer center dedicated to delivering the highest level of care for patients with pancreatic cancer. The center is led by Executive Director Peter Allen, MD, and Deputy Directors Daniel Nussbaum, MD, and John Strickler, MD.The DCI Pancreatic Cancer Center seeks to improve long-term outcomes for patients with or at risk for pancreatic cancer through practice-changing research focusing on prevention, early detection, and treatment."While tremendous progress has been made in treating pancreatic cancer, we recognize that existing standard approaches are simply not good enough," Nussbaum said. "The mission of the DCI Pancreatic Cancer Center is to leverage our clinical and research expertise in order to develop the next generation of therapies for this disease. Our goal is to offer our patients not only standard treatments, which are critically important, but also novel therapies that might improve their chance for cure."Areas of focus include expanding genomic and molecular targeted therapy options, developing the next generation of immunotherapy treatments, and creating novel early detection technologies for pre-malignant or early-stage pancreatic cancer.Patients will have access to innovative clinical trials and individualized treatment protocols through the center."The DCI Pancreatic Cancer Center unites scientists, clinical-investigators, and clinicians toward the shared goal of improving pancreatic cancer survival," Strickler said.
